TD Cowen Boosts GeneDx (NASDAQ:WGS) Price Target to $118.00

GeneDx (NASDAQ:WGSGet Free Report) had its price objective upped by research analysts at TD Cowen from $75.00 to $118.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. TD Cowen’s price target indicates a potential upside of 22.19% from the stock’s current price.

Other equities analysts also recently issued research reports about the stock. Craig Hallum boosted their price objective on shares of GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. The Goldman Sachs Group boosted their price target on GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Finally, Wells Fargo & Company raised their price objective on GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 30th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $70.67.

Check Out Our Latest Analysis on WGS

GeneDx Stock Down 0.5 %

Shares of NASDAQ:WGS opened at $96.57 on Tuesday. The business’s 50 day moving average is $77.48 and its 200 day moving average is $52.46. The stock has a market cap of $2.65 billion, a P/E ratio of -31.05 and a beta of 2.02. GeneDx has a 52-week low of $2.85 and a 52-week high of $98.87. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25.

GeneDx (NASDAQ:WGSGet Free Report) last issued its earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.25. The business had revenue of $76.90 million during the quarter, compared to analysts’ expectations of $64.98 million. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The business’s revenue for the quarter was up 44.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.82) EPS. Sell-side analysts predict that GeneDx will post -0.24 EPS for the current year.

Insider Activity

In other GeneDx news, CFO Kevin Feeley sold 1,137 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $76.37, for a total transaction of $86,832.69. Following the sale, the chief financial officer now owns 24,731 shares of the company’s stock, valued at approximately $1,888,706.47. The trade was a 4.40 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Katherine Stueland sold 2,154 shares of GeneDx stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $66.60, for a total transaction of $143,456.40. Following the sale, the chief executive officer now owns 105,426 shares of the company’s stock, valued at $7,021,371.60. The trade was a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,143,039 shares of company stock worth $84,816,828. Insiders own 27.30% of the company’s stock.

Institutional Trading of GeneDx

Several large investors have recently made changes to their positions in the business. Driehaus Capital Management LLC acquired a new stake in GeneDx during the second quarter worth about $11,335,000. Fred Alger Management LLC acquired a new stake in shares of GeneDx during the 3rd quarter worth approximately $16,731,000. Divisadero Street Capital Management LP purchased a new position in shares of GeneDx during the 2nd quarter valued at approximately $5,886,000. Millennium Management LLC lifted its stake in shares of GeneDx by 193.5% in the 2nd quarter. Millennium Management LLC now owns 311,401 shares of the company’s stock valued at $8,140,000 after purchasing an additional 205,318 shares during the period. Finally, Raymond James & Associates purchased a new stake in GeneDx during the third quarter worth $8,090,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

GeneDx Company Profile

(Get Free Report)

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

Featured Articles

Analyst Recommendations for GeneDx (NASDAQ:WGS)

Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.